Shares of CG Oncology, Inc. (NASDAQ:CGON - Get Free Report) have been given an average rating of "Buy" by the twelve ratings firms that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation, ten have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $57.70.
CGON has been the topic of a number of research reports. TD Cowen initiated coverage on CG Oncology in a research report on Tuesday, January 7th. They set a "buy" rating on the stock. Cantor Fitzgerald restated an "overweight" rating and set a $75.00 price target on shares of CG Oncology in a report on Monday, April 28th. Royal Bank of Canada raised their price objective on shares of CG Oncology from $66.00 to $68.00 and gave the company an "outperform" rating in a report on Tuesday, April 29th. JPMorgan Chase & Co. initiated coverage on shares of CG Oncology in a research report on Friday. They issued an "overweight" rating and a $41.00 price target for the company. Finally, Scotiabank assumed coverage on shares of CG Oncology in a report on Wednesday, April 16th. They set a "sector perform" rating and a $23.00 price target on the stock.
Get Our Latest Stock Report on CG Oncology
CG Oncology Trading Down 23.0 %
NASDAQ CGON traded down $6.48 during trading on Friday, hitting $21.70. 4,284,102 shares of the company's stock were exchanged, compared to its average volume of 793,812. The company has a market cap of $1.65 billion, a PE ratio of -15.28 and a beta of 1.08. CG Oncology has a fifty-two week low of $14.80 and a fifty-two week high of $40.47. The stock's 50 day moving average price is $23.68 and its two-hundred day moving average price is $28.80.
CG Oncology (NASDAQ:CGON - Get Free Report) last released its quarterly earnings data on Tuesday, March 25th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.11). The company had revenue of $0.46 million for the quarter, compared to analyst estimates of $0.11 million. CG Oncology had a negative return on equity of 18.97% and a negative net margin of 10,642.98%. Analysts forecast that CG Oncology will post -1.31 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other news, Director Leonard E. Post sold 1,000 shares of the company's stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $30.76, for a total transaction of $30,760.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of CGON. KLP Kapitalforvaltning AS increased its position in shares of CG Oncology by 131.4% during the first quarter. KLP Kapitalforvaltning AS now owns 8,100 shares of the company's stock worth $198,000 after acquiring an additional 4,600 shares in the last quarter. Teachers Retirement System of The State of Kentucky acquired a new position in CG Oncology during the 1st quarter valued at about $605,000. Massachusetts Financial Services Co. MA increased its holdings in CG Oncology by 0.4% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 258,090 shares of the company's stock worth $6,321,000 after purchasing an additional 933 shares in the last quarter. CWM LLC raised its stake in shares of CG Oncology by 3,957.7% in the first quarter. CWM LLC now owns 2,110 shares of the company's stock worth $52,000 after purchasing an additional 2,058 shares during the last quarter. Finally, Alps Advisors Inc. lifted its holdings in shares of CG Oncology by 3.1% in the first quarter. Alps Advisors Inc. now owns 56,399 shares of the company's stock valued at $1,381,000 after purchasing an additional 1,709 shares in the last quarter. Institutional investors and hedge funds own 26.56% of the company's stock.
About CG Oncology
(
Get Free ReportCG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.
Further Reading
Before you consider CG Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CG Oncology wasn't on the list.
While CG Oncology currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
